[开放获取]    中国天疱疮诊疗指南（2024版）

doi:10.35541/cjd.20240222

Abstract

Abstract: 【Abstract】 Pemphigus is a group of rare and severe autoimmune bullous diseases characterized by blisters, bullae, and erosions on the skin and/or mucous membranes. With the deep understanding of pemphigus and continuous update of treatment methods, it is necessary to formulate guidelines for the diagnosis and treatment of pemphigus in China. Hence, a guideline working group was established by relevant academic organizations. Based on available evidence in China and other countries, as well as China's national conditions, 12 clinical issues that need to be urgently solved were proposed and 30 recommendations were formulated on the diagnosis and treatment of pemphigus after multiple rounds of demonstration and selection, aiming to provide a reference for the diagnosis and treatment of pemphigus and to guide clinical practice.

Key words: Pemphigus, Diagnosis, Treatment, Glucocorticoids, Rituximab, Immunosuppressive agents, Guideline

China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Guidelines for diagnosis and treatment of pemphigus in China （2024）[J]. Chinese Journal of Dermatology, 2024, 57(10): 873-886.doi:10.35541/cjd.20240222

References ［74］

［1］	中国医师协会皮肤科医师分会, 疑难重症及罕见病国家重点实验室, 国家皮肤与免疫疾病临床医学研究中心. 天疱疮患者健康教育共识（2023版）［J］. 中华皮肤科杂志, 2023:e20230123. doi:10.35541/cjd.20230123:
［2］	Schmidt E, Kasperkiewicz M, Joly P. Pemphigus［J］. Lancet, 2019,394（10201）:882⁃894. doi: 10.1016/S0140⁃6736（19）31778⁃7.
［3］	张晓, 朱冠男, 张少龙, 等. 182例天疱疮患者合并感染状况的回顾分析［J］. 中华皮肤科杂志, 2020,53（1）:8⁃12. doi: 10.35541/cjd.20190382.
［4］	国家卫生健康委，科技部，工业和信息化部, 等.关于公布第二批罕见病目录的通知［J］. 中华人民共和国国家卫生健康委员会公报, 2023,238（9）:11⁃14.
［5］	Zhao W, Wang J, Zhu H, et al. Comparison of guidelines for management of pemphigus: a review of systemic corticosteroids, rituximab, and other immunosuppressive therapies［J］. Clin Rev Allergy Immunol, 2021,61（3）:351⁃362. doi: 10.1007/s12016⁃021⁃08882⁃1.
［6］	中国医师协会皮肤科医师分会自身免疫疾病亚专业委员会. 寻常型天疱疮诊断和治疗的专家建议［J］. 中华皮肤科杂志, 2016,49（11）:761⁃765. doi: 10.3760/cma.j.issn.0412⁃4030.2016. 11.01.
［7］	中国医疗保健国际交流促进会皮肤科分会. 寻常型天疱疮诊断和治疗专家建议（2020）［J］. 中华皮肤科杂志, 2020,53（1）:1⁃7. doi: 10.35541/cjd.20190703.
［8］	Zhang J, Huang X, Zhang Z, et al. Clinical observation of different doses of rituximab for the treatment of severe pemphigus: a single⁃center prospective cohort study［J］. J Am Acad Dermatol, 2023,88（2）:500⁃502. doi: 10.1016/j.jaad.2022. 06.1187.
［9］	陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则（2022版）［J］. 中华医学杂志, 2022,102（10）:697⁃703. doi: 10.3760/cma.j.cn112137⁃20211228⁃02911.
［10］	Ghaedi F, Etesami I, Aryanian Z, et al. Drug⁃induced pemphigus: a systematic review of 170 patients［J］. Int Immunopharmacol, 2021,92:107299. doi: 10.1016/j.intimp.2020. 107299.
［11］	Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts［J］. J Am Acad Dermatol, 2020,82（3）:575⁃585.e1. doi: 10. 1016/j.jaad.2018.02.021.
［12］	Chowdhury J, Datta PK, Chowdhury SN, et al. A clinicopathological study of pemphigus in Eastern India with special reference to direct immunofluorescence［J］. Indian J Dermatol, 2016,61（3）:288⁃294. doi: 10.4103/0019⁃5154.182422.
［13］	闫言, 徐浩翔, 晋红中, 等. ELISA技术检测寻常型天疱疮桥粒芯蛋白3抗体水平研究［J］. 临床皮肤科杂志, 2011,40（9）:529⁃531. doi: 10.3969/j.issn.1000⁃4963.2011.09.005.
［14］	Committee for Guidelines for the Management of Pemphigus Disease. Japanese guidelines for the management of pemphigus［J］. J Dermatol, 2014,41（6）:471⁃486. doi: 10.1111/1346⁃8138.12486.
［15］	Endo H, Rees TD, Matsue M, et al. Early detection and successful management of oral pemphigus vulgaris: a case report［J］. J Periodontol, 2005,76（1）:154⁃160. doi: 10.1902/jop.2005. 76.1.154.
［16］	Rahbar Z, Daneshpazhooh M, Mirshams⁃Shahshahani M, et al. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score［J］. JAMA Dermatol, 2014,150（3）:266⁃272. doi: 10.1001/jamadermatol.2013.8175.
［17］	Shimizu T, Takebayashi T, Sato Y, et al. Grading criteria for disease severity by pemphigus disease area index［J］. J Dermatol, 2014,41（11）:969⁃973. doi: 10.1111/1346⁃8138.12649.
［18］	Hébert V, Boulard C, Houivet E, et al. Large international validation of ABSIS and PDAI pemphigus severity scores［J］. J Invest Dermatol, 2019,139（1）:31⁃37. doi: 10.1016/j.jid.2018. 04.042.
［19］	Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus［J］. J Invest Dermatol, 2009,129（10）:2404⁃2410. doi: 10.1038/jid.2009.72.
［20］	Boulard C, Duvert Lehembre S, Picard⁃Dahan C, et al. Calculation of cut⁃off values based on the Autoimmune Bullous Skin Disorder Intensity Score （ABSIS） and Pemphigus Disease Area Index （PDAI） pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus［J］. Br J Dermatol, 2016,175（1）:142⁃149. doi: 10.1111/bjd.14405.
［21］	Harman KE, Seed PT, Gratian MJ, et al. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels［J］. Br J Dermatol, 2001,144（4）:775⁃780. doi: 10.1046/j.1365⁃2133.2001.04132.x.
［22］	Daneshpazhooh M, Chams⁃Davatchi C, Khamesipour A, et al. Desmoglein 1 and 3 enzyme⁃linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity［J］. J Eur Acad Dermatol Venereol, 2007,21（10）:1319⁃1324. doi: 10.1111/j.1468⁃3083. 2007.02254.x.
［23］	Lee MS, Yeh YC, Tu YK, et al. Network meta⁃analysis⁃based comparison of first⁃line steroid⁃sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus［J］. J Am Acad Dermatol, 2021,85（1）:176⁃186. doi: 10.1016/j.jaad. 2020.08.028.
［24］	Joly P, Maho⁃Vaillant M, Prost⁃Squarcioni C, et al. First⁃line rituximab combined with short⁃term prednisone versus prednisone alone for the treatment of pemphigus （Ritux 3）: a prospective, multicentre, parallel⁃group, open⁃label randomised trial［J］. Lancet, 2017,389（10083）:2031⁃2040. doi: 10.1016/S0140⁃6736（17）30070⁃3.
［25］	中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员会. 糖皮质激素治疗免疫相关性皮肤病专家共识（2018年）［J］. 中华临床免疫和变态反应杂志, 2018,12（1）:1⁃7. doi: 10.3969/j.issn.1673⁃8705.2018.01.001.
［26］	Mignard C, Maho⁃Vaillant M, Golinski ML, et al. Factors associated with short⁃term relapse in patients with pemphigus who receive rituximab as first⁃line therapy: a post hoc analysis of a randomized clinical trial［J］. JAMA Dermatol, 2020,156（5）:545⁃552. doi: 10.1001/jamadermatol.2020.0290.
［27］	中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 糖皮质激素类药物临床应用指导原则（2023版）［J］. 中华内分泌代谢杂志, 2023,39（4）:289⁃296. doi: 10.3760/cma.j.cn311282⁃20230116⁃00029.
［28］	Chovatiya R, Silverberg JI. Association of pemphigus and pemphigoid with osteoporosis and pathological fractures［J］. Arch Dermatol Res, 2020,312（4）:263⁃271. doi: 10.1007/s00403⁃019⁃02010⁃y.
［29］	Patel PM, Amber KT. The risk of Pneumocystis pneumonia in patients of autoimmune blistering disease⁃reply to letter entitled "Pemphigus management guidelines: a life⁃saving perspective"［J］. J Am Acad Dermatol, 2021,85（5）:e289. doi: 10.1016/j.jaad.2021.04.106.
［30］	Werth VP, Joly P, Mimouni D, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris［J］. N Engl J Med, 2021,384（24）:2295⁃2305. doi: 10.1056/NEJMoa 2028564.
［31］	Russo I, Miotto S, Saponeri A, et al. Ultra⁃low dose rituximab for refractory pemghigus vulgaris: a pilot study［J］. Expert Opin Biol Ther, 2020,20（6）:673⁃678. doi: 10.1080/14712598.2020.172 7440.
［32］	Zhou X, Zhan T, Xu X, et al. The efficacy and safety of low⁃dose rituximab in the treatment of pemphigus vulgaris: a cohort study［J］. J Dermatolog Treat, 2024,35（1）:2302071. doi: 10.1080/09546634.2024.2302071.
［33］	Salopek TG, Logsetty S, Tredget EE. Anti⁃CD20 chimeric monoclonal antibody （rituximab） for the treatment of recalcitrant, life⁃threatening pemphigus vulgaris with implications in the pathogenesis of the disorder［J］. J Am Acad Dermatol, 2002,47（5）:785⁃788. doi: 10.1067/mjd.2002.126273.
［34］	Tedbirt B, Maho⁃Vaillant M, Houivet E, et al. Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first⁃line therapy: follow⁃up of the Ritux 3 Trial［J］. JAMA Dermatol, 2024,160（3）:290⁃296. doi: 10.1001/jamadermatol.2023.5679.
［35］	Kridin K, Mruwat N, Amber KT, et al. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large⁃scale global cohort study［J］. Br J Dermatol, 2023,188（4）:499⁃505. doi: 10.1093/bjd/ljac118.
［36］	Chang Y, Chen X, Wang M, et al. A 10⁃year retrospective cohort analysis of rituximab for the treatment of pemphigus in a Chinese population［J］. J Am Acad Dermatol, 2021,85（6）:1643⁃1645. doi: 10.1016/j.jaad.2020.12.062.
［37］	张春燕, 邢丽秋, 钟蕾, 等. 2003⁃2019年北京市利妥昔单抗不良反应报告分析［J］. 中国新药杂志, 2020,29（18）:2157⁃2160. doi: 10.3969/j.issn.1003⁃3734.2020.18.020.
［38］	Daneshpazhooh M, Balighi K, Mahmoudi H, et al. Iranian guideline for rituximab therapy in pemphigus patients［J］. Dermatol Ther, 2019,32（5）:e13016. doi: 10.1111/dth.13016.
［39］	Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2020,34（9）:1900⁃1913. doi: 10.1111/jdv.16752.
［40］	Chams⁃Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris［J］. J Eur Acad Dermatol Venereol, 2013,27（10）:1285⁃1292. doi: 10.1111/j.1468⁃3083.2012.04717.x.
［41］	Beissert S, Mimouni D, Kanwar AJ, et al. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo⁃controlled trial［J］. J Invest Dermatol, 2010,130（8）:2041⁃2048. doi: 10.1038/jid.2010.91.
［42］	Zhou X, Cheng L, Wang Y, et al. Effect of NUDT15 polymorphisms on early hematological safety of low⁃dose azathioprine in Chinese patients with pemphigus vulgaris: a prospective cohort study［J］. J Dermatol, 2022,49（4）:402⁃410. doi: 10.1111/1346⁃8138.16265.
［43］	中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议［J］. 中华皮肤科杂志, 2021,54（2）:116⁃121. doi: 10.35541/cjd.20200469.
［44］	Kolla A, Shah P, Cymerman R, et al. Assessing the use of methotrexate as an alternate therapy for pemphigus vulgaris and pemphigus foliaceus［J］. Dermatol Ther, 2022,35（8）:e15661. doi: 10.1111/dth.15661.
［45］	高奥, 郭代红, 姚翀, 等. 4826例免疫抑制剂及相关器官移植用药致药品不良反应自发报告分析［J］. 中国医院用药评价与分析, 2020,20（4）:484⁃488. doi: 10.14009/j.issn.1672⁃2124. 2020.04.026.
［46］	中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识［J］. 中华皮肤科杂志, 2021,54（5）:382⁃390. doi: 10.35541/cjd.20200796.
［47］	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识［J］. 中华皮肤科杂志, 2021,54（9）:765⁃770. doi: 10.35541/cjd.20210039.
［48］	Chu CY, Lee CH, Lee HE, et al. Taiwanese dermatological association （TDA） consensus for the management of pemphigus［J］. J Formos Med Assoc, 2023,122（7）:540⁃548. doi: 10.1016/j.jfma.2022.12.005.
［49］	Amagai M, Ikeda S, Shimizu H, et al. A randomized double⁃blind trial of intravenous immunoglobulin for pemphigus［J］. J Am Acad Dermatol, 2009,60（4）:595⁃603. doi: 10.1016/j.jaad. 2008.09.052.
［50］	Higashihara T, Kawase M, Kobayashi M, et al. Evaluating the efficacy of double⁃filtration plasmapheresis in treating five patients with drug⁃resistant pemphigus［J］. Ther Apher Dial, 2017,21（3）:243⁃247. doi: 10.1111/1744⁃9987.12557.
［51］	Schmidt E, Zillikens D. Immunoadsorption in dermatology［J］. Arch Dermatol Res, 2010,302（4）:241⁃253. doi: 10.1007/s00403⁃009⁃1024⁃9.
［52］	van Beek N, Eming R, Reuss A, et al. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus （IA⁃Pem Study）: a multicentre randomized controlled trial［J］. Br J Dermatol, 2024,190（5）:657⁃667. doi: 10.1093/bjd/ljad489.
［53］	Nosrati A, Hodak E, Mimouni T, et al. Treatment of pemphigus with rituximab: real⁃life experience in a cohort of 117 patients in Israel［J］. Dermatology, 2021,237（3）:450⁃456. doi: 10.1159/000513515.
［54］	Ahmed AR, Kalesinskas M, Kaveri SV. Restoring immune tolerance in pemphigus vulgaris［J］. Proc Natl Acad Sci U S A, 2024,121（5）:e2317762121. doi: 10.1073/pnas.2317762121.
［55］	Fuertes I, Guilabert A, Mascaró JM Jr, et al. Rituximab in childhood pemphigus vulgaris: a long⁃term follow⁃up case and review of the literature［J］. Dermatology, 2010,221（1）:13⁃16. doi: 10.1159/000287254.
［56］	Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017［J］. Br J Dermatol, 2017,177（5）:1170⁃1201. doi: 10.1111/bjd.15930.
［57］	Foster ML, Spaulding RT, Schadt CR. Neonatal pemphigus vulgaris［J］. JAMA Dermatol, 2021,157（2）:220. doi: 10.1001/jamadermatol.2020.3990.
［58］	Lan Y, Zhang H, Jin H. Pregnancy in pemphigus vulgaris: a systematic review［J］. Am J Reprod Immunol, 2024,91（1）:e13813. doi: 10.1111/aji.13813.
［59］	Kushner CJ, Concha J, Werth VP. Treatment of autoimmune bullous disorders in pregnancy［J］. Am J Clin Dermatol, 2018,19（3）:391⁃403. doi: 10.1007/s40257⁃018⁃0342⁃0.
［60］	中国医师协会皮肤科医师分会自身免疫性疾病专业委员会. 吗替麦考酚酯治疗免疫相关性皮肤病专家建议［J］. 中华皮肤科杂志, 2020,53（11）:869⁃874. doi: 10.35541/cjd.20200306.
［61］	中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员. 大疱性类天疱疮诊断和治疗的专家建议［J］. 中华皮肤科杂志, 2016,49（6）:384⁃387. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.06.003.
［62］	Tehranchi⁃Nia Z, Qureshi TA, Ahmed AR. Pemphigus vulgaris in older adults［J］. J Am Geriatr Soc, 1998,46（1）:92⁃94. doi: 10.1111/j.1532⁃5415.1998.tb01020.x.
［63］	Ingen⁃Housz⁃Oro S, Alexandre M, Le Roux⁃Villet C, et al. Pemphigus in elderly adults: clinical presentation, treatment, and prognosis［J］. J Am Geriatr Soc, 2012,60（6）:1185⁃1187. doi: 10.1111/j.1532⁃5415.2012.03987.x.
［64］	Zaraa I, Sellami A, Bouguerra C, et al. Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study［J］. J Eur Acad Dermatol Venereol, 2011,25（10）:1160⁃1167. doi: 10.1111/j.1468⁃3083.2010.03939.x.
［65］	Ruocco V, Ruocco E, Caccavale S, et al. Pemphigus vegetans of the folds （intertriginous areas）［J］. Clin Dermatol, 2015,33（4）:471⁃476. doi: 10.1016/j.clindermatol.2015.04.011.
［66］	Pritchett EN, Hejazi E, Cusack CA. Pruritic, pink scaling plaques on the face and trunk. Pemphigus erythematosus［J］. JAMA Dermatol, 2015,151（10）:1123⁃1124. doi: 10.1001/jamadermatol.2015.2103.
［67］	Hobbs LK, Noland MB, Raghavan SS, et al. Pemphigus erythematosus: a case series from a tertiary academic center and literature review［J］. J Cutan Pathol, 2021,48（8）:1038⁃1050. doi: 10.1111/cup.13992.
［68］	Kridin K, Patel PM, Jones VA, et al. IgA pemphigus: a systematic review［J］. J Am Acad Dermatol, 2020,82（6）:1386⁃1392. doi: 10.1016/j.jaad.2019.11.059.
［69］	Wang YM, Mao XM, Zhao WL, et al. The clinical, immunological and pathological features for relapse of pemphigus herpetiformis: a univariate analysis of 26 cases［J］. Br J Dermatol, 2020,182（3）:802⁃804. doi: 10.1111/bjd.18518.
［70］	Costa L, Cappel MA, Keeling JH. Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria［J］. Int J Dermatol, 2019,58（9）:997⁃1007. doi: 10.1111/ijd.14395.
［71］	Laws PM, Heelan K, Al⁃Mohammedi F, et al. Pemphigus herpetiformis: a case series and review of the literature［J］. Int J Dermatol, 2015,54（9）:1014⁃1022. doi: 10.1111/ijd.12582.
［72］	Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2023,37（6）:1118⁃1134. doi: 10.1111/jdv.18931.
［73］	Zhang X, Xiao Y, Li X, et al. Ofatumumab subcutaneous injection successfully treated patients with pemphigus vulgaris relapse post rituximab［J］. J Dermatol, 2024,51（7）:1026⁃1030. doi: 10.1111/1346⁃8138.17108.
［74］	Yanovsky RL, McLeod M, Ahmed AR. Treatment of pemphigus vulgaris: part 2 ⁃ emerging therapies［J］. Expert Rev Clin Immunol, 2019,15（10）:1061⁃1071. doi: 10.1080/1744666X.2020.1672539.

[1]	Lu Qing, Liu Yanqiu, Liu Danping, Zou Yongyi, Yang Bicheng. Variation analysis and prenatal diagnosis in a pedigree with oculocutaneous albinism [J]. Chinese Journal of Dermatology, 2024, 57(9): 842-843.
[2]	Zou Xianbiao, Chen Jinchun, Zeng Yue, Hao Yi. Application of ultrasonography in dermatology: progress and prospects [J]. Chinese Journal of Dermatology, 2024, 57(9): 785-790.
[3]	Zeng Yue, Shao Huihong, Lin Shiwen, Wen Rou, Zou Xianbiao. Application of a wearable teleconsultation device in diagnosis of common skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(9): 797-800.
[4]	He Lan, Ma Ling, Jiang Qian, Chen Liuqing, Chen Hongying. Analysis of dermoscopic and reflectance confocal microscopic characteristics of 57 cases of extragenital lichen sclerosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 791-796.
[5]	Combination of Traditional and Western Medicine Dermatology, Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the application of reflectance confocal microscopy in common melanocytic skin tumors（2024） [J]. Chinese Journal of Dermatology, 2024, 57(9): 775-784.
[6]	Xie yuanyuan, Liu Yuzhen, Zeng Rong, . Application of skin imaging techniques in acne vulgaris [J]. Chinese Journal of Dermatology, 2024, 57(8): 757-760.
[7]	Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 57(8): 743-746.
[8]	Xia Manqi, Shao Lei, Huang Qiongxiao, Tian Xin, Liang Yimin, Huang Ting, Liang Jingyao, Liu Yumei. Efficacy and safety of dupilumab in the treatment of prurigo nodularis: a multicenter retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(8): 679-684.
[9]	Liu Qingfeng, Liu Lian, Diao Ping, Li Xiaoxue, Zhang Ting, Chen Haotian, Liu Xu, Jiang Xian. Diagnosis and treatment of port-wine stains-associated syndromes [J]. Chinese Journal of Dermatology, 2024, 57(7): 656-660.
[10]	Diao Ping, Han Chenglong, Liu Lian, Zhou Hui, Li Erlong, Jiang Xian. Efficacy and influencing factors of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of adult patients with port-wine stains: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(7): 595-600.
[11]	Zhang Ting, Liu Lian, Chen Haotian, Wei Danfeng, Liu Xu, Diao Ping, Liu Qingfeng, Jiang Xian. Efficacy of 595-nm pulsed dye laser in the treatment of port‐wine stains in 155 infants and toddlers: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(7): 610-615.
[12]	Wang Linxia, Zhang Liming, Shi Meihui, Gao Xinghua, Chen Hongduo, Xiao Ting. Clinical features of 131 patients with chronic spontaneous urticaria accompanied by angioedema or not: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(6): 510-515.
[13]	aser Cosmetology Group, Medical Aesthetics and Cosmetology Branch of Chinese Medical Association, Skin Care Product and Material Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment, Laser Group, Cosmetic and Plastic Surgeon Branch of Chinese Medical Doctor Association, Cosmetic Laser Group, Chinese Society of Dermatology. Guidelines for the diagnosis and treatment of adverse skin reactions to cosmetics （2024 edition） [J]. Chinese Journal of Dermatology, 2024, 57(6): 485-492.
[14]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China （2024） [J]. Chinese Journal of Dermatology, 2024, 0(5): 20240294-e20240294.
[15]	Hou Xiaoyuan, Wu Nanhui, Xu Mingyuan, Liu Yeqiang. A case of granuloma annulare treated with the JAK inhibitor baricitinib [J]. Chinese Journal of Dermatology, 2024, 57(5): 461-462.

Guidelines for diagnosis and treatment of pemphigus in China （2024）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［74］

Related Articles 15

Metrics

Comments

Recommended 10